Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland

Sarah Shuk Kay Tang (Lead / Corresponding author), Sarantos Kaptanis, James B. Haddow, Giuseppina Mondani, Beatrix Elsberger, Marios Konstantinos Tasoulis, Christine Obondo, Neil Johns, Wisam Ismail, Asim Syed, Panayioti Kissias, Mary Venn, Souganthy Sundaramoorthy, Gareth Irwin, Amtul S. Sami, Dalia Elfadl, Alice Baggaley, Dionysios Dennis Remoundos, Fiona Langlands, Petros CharalampoudisZoe Barber, Werbena L.S. Hamilton-Burke, Ayesha Khan, Chiara Sirianni, Louise Anne Marie Grant Merker, Sunita Saha, Risha Arun Lane, Sharat Chopra, Sophie Dupré, Aiden T. Manning, Edward R. St John, Aya Musbahi, Nokwanda Dlamini, Caitlin L. McArdle, Chloe Wright, James O. Murphy, Ravi Aggarwal, Matei Dordea, Karen Bosch, Donna Egbeare, Hisham Osman, Salim Tayeh, Faraz Razi, Javeria Iqbal, Serena F.C. Ledwidge, Vanessa Albert

    Research output: Contribution to journalArticle

    21 Citations (Scopus)
    426 Downloads (Pure)

    Abstract

    Introduction: There is variation in margin policy for breast conserving therapy (BCT) in the UK and Ireland. In response to the Society of Surgical Oncology and American Society for Radiation Oncology (SSO-ASTRO) margin consensus (‘no ink on tumour’ for invasive and 2 mm for ductal carcinoma in situ [DCIS]) and the Association of Breast Surgery (ABS) consensus (1 mm for invasive and DCIS), we report on current margin practice and unit infrastructure in the UK and Ireland and describe how these factors impact on re-excision rates.

    Methods: A trainee collaborative-led multicentre prospective study was conducted in the UK and Ireland between 1st February and 31st May 2016. Data were collected on consecutive BCT patients and on local infrastructure and policies.

    Results: A total of 79 sites participated in the data collection (75% screening units; average 372 cancers annually, range 70–900). For DCIS, 53.2% of units accept 1 mm and 38% accept 2-mm margins. For invasive disease 77.2% accept 1 mm and 13.9% accept ‘no ink on tumour’. A total of 2858 patients underwent BCT with a mean re-excision rate of 17.2% across units (range 0–41%). The re-excision rate would be reduced to 15% if all units applied SSO-ASTRO guidelines and to 14.8% if all units followed ABS guidelines. Of those who required re-operation, 65% had disease present at margin.

    Conclusion: There continues to be large variation in margin policy and re-excision rates across units. Altering margin policies to follow either SSO-ASTRO or ABS guidelines would result in a modest reduction in the national re-excision rate. Most re-excisions are for involved margins rather than close margins.

    Original languageEnglish
    Pages (from-to)315-324
    Number of pages10
    JournalEuropean Journal of Cancer
    Volume84
    Early online date30 Aug 2017
    DOIs
    Publication statusPublished - 1 Oct 2017

    Keywords

    • ABS
    • Breast cancer
    • Breast-conserving therapy
    • Consensus guidelines
    • Margins
    • Re-excision
    • Re-operation
    • SSO-ASTRO

    Fingerprint Dive into the research topics of 'Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland'. Together they form a unique fingerprint.

  • Cite this

    Tang, S. S. K., Kaptanis, S., Haddow, J. B., Mondani, G., Elsberger, B., Tasoulis, M. K., Obondo, C., Johns, N., Ismail, W., Syed, A., Kissias, P., Venn, M., Sundaramoorthy, S., Irwin, G., Sami, A. S., Elfadl, D., Baggaley, A., Remoundos, D. D., Langlands, F., ... Albert, V. (2017). Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland. European Journal of Cancer, 84, 315-324. https://doi.org/10.1016/j.ejca.2017.07.032